{"id":62555,"date":"2026-04-07T21:24:25","date_gmt":"2026-04-07T13:24:25","guid":{"rendered":"https:\/\/flcube.com\/?p=62555"},"modified":"2026-04-07T21:24:27","modified_gmt":"2026-04-07T13:24:27","slug":"china-imposes-historic-four-year-vbp-ban-on-fu-kang-ren-hetero-labs-for-supply-failures-hehe-and-tiantaishan-also-penalized","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62555","title":{"rendered":"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized"},"content":{"rendered":"\n<p>The <strong>National Drug Alliance Procurement Office<\/strong> has revoked the <strong>Volume-Based Procurement (VBP)<\/strong> winning bid qualifications of <strong>three drugs<\/strong> and imposed unprecedented penalties on four pharmaceutical firms for <strong>failure to fulfill supply obligations<\/strong>\u2014marking the <strong>strictest enforcement action in VBP history<\/strong>.<\/p>\n\n\n\n<p>The affected products include <strong>dopamine<\/strong> (Beijing Fu Kang Ren Bio-pharm Tech), <strong>dapagliflozin<\/strong> (Hetero Labs Limited), and <strong>methocarbamol<\/strong> (Guangzhou Hehe Pharmaceutical), along with its contract manufacturer, <strong>Chengdu Tiantaishan Pharmaceutical<\/strong>. All four companies have been <strong>blacklisted<\/strong> from future VBP rounds, with bans ranging from <strong>18 months to four years<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-enforcement-summary\">Enforcement Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Product<\/th><th>VBP Round Won<\/th><th>Penalty Period<\/th><th>Reason<\/th><\/tr><\/thead><tbody><tr><td><strong>Beijing Fu Kang Ren Bio-pharm<\/strong><\/td><td>Dopamine<\/td><td>Round 9<\/td><td><strong>03 Apr 2026 \u2013 02 Apr 2030<\/strong><\/td><td>Failed to supply contracted volumes despite follow-up<\/td><\/tr><tr><td><strong>Hetero Labs Limited<\/strong><\/td><td>Dapagliflozin<\/td><td>Round 11<\/td><td><strong>03 Apr 2026 \u2013 02 Apr 2030<\/strong><\/td><td>Same as above<\/td><\/tr><tr><td><strong>Guangzhou Hehe Pharmaceutical<\/strong><\/td><td>Methocarbamol<\/td><td>\u2014<\/td><td><strong>02 Apr 2026 \u2013 01 Oct 2027<\/strong><\/td><td>Supply chain failure (with CMO)<\/td><\/tr><tr><td><strong>Chengdu Tiantaishan Pharma<\/strong><\/td><td>(CMO for methocarbamol)<\/td><td>\u2014<\/td><td><strong>02 Apr 2026 \u2013 01 Oct 2027<\/strong><\/td><td>Co-responsible for non-delivery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-background-amp-regulatory-context\">Background &amp; Regulatory Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>VBP Program<\/strong>: China\u2019s cornerstone drug pricing reform, covering >90% of public hospital procurement volume for selected generics and off-patent drugs<\/li>\n\n\n\n<li><strong>Winning Bid Obligation<\/strong>: Awardees must guarantee <strong>continuous, nationwide supply<\/strong> at the bid price for the entire contract period (typically 2\u20133 years)<\/li>\n\n\n\n<li><strong>Escalation Process<\/strong>: The Procurement Office conducted multiple rounds of <strong>remedial discussions<\/strong> before imposing penalties, citing \u201cpersistent inability to meet institutional demand\u201d<\/li>\n\n\n\n<li><strong>Precedent<\/strong>: Previous violations resulted in 6\u201312 month suspensions; this <strong>four-year ban<\/strong> signals a hardening stance on supply reliability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-strategic-implications\">Market &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Impact<\/strong>: Hospitals must source dopamine and dapagliflozin from <strong>higher-priced backup suppliers<\/strong>, potentially increasing short-term costs<\/li>\n\n\n\n<li><strong>Reputational Risk<\/strong>: Blacklisted firms face exclusion not only from VBP but also from provincial tenders and hospital formularies that reference national lists<\/li>\n\n\n\n<li><strong>Investor Caution<\/strong>: Foreign generic manufacturers (e.g., Hetero Labs, India) now face heightened scrutiny over <strong>China-specific supply chain resilience<\/strong><\/li>\n\n\n\n<li><strong>Policy Signal<\/strong>: Authorities prioritize <strong>supply security over lowest price<\/strong>, reinforcing that VBP is not just a cost-cutting tool but a <strong>national essential medicines assurance mechanism<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief reflects official regulatory actions as of 07 Apr 2026. Future participation eligibility remains subject to compliance verification by Chinese health authorities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[82],"class_list":["post-62555","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-vbp-voluem-based-procurement"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications of three drugs and imposed unprecedented penalties on four pharmaceutical firms for failure to fulfill supply obligations\u2014marking the strictest enforcement action in VBP history.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62555\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized\" \/>\n<meta property=\"og:description\" content=\"The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications of three drugs and imposed unprecedented penalties on four pharmaceutical firms for failure to fulfill supply obligations\u2014marking the strictest enforcement action in VBP history.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62555\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T13:24:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T13:24:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62555#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62555\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized\",\"datePublished\":\"2026-04-07T13:24:25+00:00\",\"dateModified\":\"2026-04-07T13:24:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62555\"},\"wordCount\":359,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"VBP (voluem-based procurement)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62555#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62555\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62555\",\"name\":\"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-07T13:24:25+00:00\",\"dateModified\":\"2026-04-07T13:24:27+00:00\",\"description\":\"The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications of three drugs and imposed unprecedented penalties on four pharmaceutical firms for failure to fulfill supply obligations\u2014marking the strictest enforcement action in VBP history.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62555#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62555\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62555#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized - Insight, China&#039;s Pharmaceutical Industry","description":"The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications of three drugs and imposed unprecedented penalties on four pharmaceutical firms for failure to fulfill supply obligations\u2014marking the strictest enforcement action in VBP history.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62555","og_locale":"en_US","og_type":"article","og_title":"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized","og_description":"The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications of three drugs and imposed unprecedented penalties on four pharmaceutical firms for failure to fulfill supply obligations\u2014marking the strictest enforcement action in VBP history.","og_url":"https:\/\/flcube.com\/?p=62555","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-07T13:24:25+00:00","article_modified_time":"2026-04-07T13:24:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62555#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62555"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized","datePublished":"2026-04-07T13:24:25+00:00","dateModified":"2026-04-07T13:24:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62555"},"wordCount":359,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["VBP (voluem-based procurement)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62555#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62555","url":"https:\/\/flcube.com\/?p=62555","name":"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-07T13:24:25+00:00","dateModified":"2026-04-07T13:24:27+00:00","description":"The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications of three drugs and imposed unprecedented penalties on four pharmaceutical firms for failure to fulfill supply obligations\u2014marking the strictest enforcement action in VBP history.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62555#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62555"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62555#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62555"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62555\/revisions"}],"predecessor-version":[{"id":62556,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62555\/revisions\/62556"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}